Serum apolipoproteins (apo) B and AI were measured in a probability sample of the noninstitutionalized US civilian population, ages >4 years, which included non-Hispanic whites, non-Hispanic blacks, and Mexican-Americans. Apo B concentrations were the same in males and females, lower in black males than in other males, low in childhood (ϳ0.80 g/L) and increasing to ϳ1.2 g/L in adults, and higher in younger women on hormones. Apo AI was higher in females than males, higher in blacks than in others, remained constant from childhood to adulthood (ϳ1.35 g/L) in males, but increased with age (ϳ1.30 g/L to ϳ1.55 g/L) in females, and was higher in women taking hormones. These are the first national probability estimates of apo B and apo AI in the US and are referable to the WHO-IFCC First International Reference Materials for apo AI and B.
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Apolipoprotein AI (apo AI) 4 is the major protein component of HDL (d 1.063-1.21 kg/L) and is found primarily in this lipoprotein fraction. A small amount of apo AI can also be found unassociated with HDL and in the range d 1.21-1.25 kg/L, some of which may be associated with "nascent" HDL [1] that has been newly secreted from the liver and intestine. Apo AI is also an activator of lecithin: cholesterol acyltransferase, the enzyme responsible for the esterification of cholesterol in plasma [2] , and appears to play a role in the mobilization of excess cholesterol from cells that cannot metabolize or otherwise dispose of it. How HDL and apo AI facilitate this reverse cholesterol transport is not completely understood, but may involve both passive [3] and second messenger pathways [4] . Apo B is virtually the only protein component of LDL (d 1.019 -1.063 kg/L), and most of the circulating apo B is associated with LDL. Apo B is also a component of several other lipoproteins, including chylomicrons, VLDL (d Ͻ1.006 kg/L), IDL (d 1.006 -1.019 kg/L), lipoprotein(a) [Lp(a)], and metabolic remnants of VLDL and chylomicrons. Apo B is recognized by the LDL receptor, which functions in the delivery of cholesterol to peripheral tissues for membrane and (or) steroid hormone synthesis and to the liver for removal or reuse [5] .
By virtue of their associations with HDL and LDL, both apo AI and apo B reflect the relationships of the respective parent lipoproteins with risk for coronary heart disease (CHD) [6, 7] . The circulating concentrations of both apo AI and HDL cholesterol are lower in patients with CHD than in those without serious disease. Conversely, both apo B and LDL concentrations are increased in patients with CHD. Numerous studies, which contain comparative information about the two apolipoproteins and their respective parent lipoproteins with respect to their associations with CHD, have been conducted [6 -37] .
Although the findings have been somewhat inconsistent, the majority of studies conducted over the past decade indicated that in univariate analyses, both apolipoproteins are at least as well correlated with the presence of CHD as the parent lipoproteins [6 -31] , and both low apo AI [32, 33, 35] and high apo B [32] [33] [34] [35] [36] appear to increase the risk for future coronary events.
These observations suggest that the two apolipoproteins may provide useful information with respect to assessing risk for CHD. To this end, Contois et al. [38, 39] recently reported the distributions of apo AI and apo B, primarily in adults, in the population-based Framingham Offspring Study with the use of methods that rely on the new WHO-IFCC First International Reference Materials for Apolipoproteins AI and B as the basis for accuracy. In the present study, we measured the concentration of the two apolipoproteins in Phase 1 of the Third National Health and Nutrition Examination Survey (NHANES III). This communication presents the distributions of apo AI and apo B in persons ages 4 years or older and is the first of such studies conducted on a national scale in the US population. As was true for the Framingham Offspring Study [38, 39] , the apo AI and apo B distributions presented here also use the WHO-IFCC Reference Materials as the basis for accuracy.
Methods subjects
The procedures used in this study conformed with the ethical standards of the responsible committees of the National Center for Health Statistics, Centers for Disease Control and Prevention, and the Johns Hopkins University School of Medicine. Apo AI and apo B were measured in Phase 1 of NHANES III, which was conducted from 1988 to 1991. The population sampling procedures have been described in detail [40] . Briefly, the noninstitutionalized civilian population of the US was sampled with the use of a highly stratified, multistage probability design rather than a simple random sample design. The NHANES III Phase 1 sampling procedure consisted of four stages. In the first stage, 44 primary sampling units were selected, counties or groups of contiguous counties that together were representative of the US. In the second stage, area segments composed of city or suburban blocks were selected within each primary sampling unit. The third stage consisted of the selection of households within each segment, and the fourth stage, individuals within households. The NHANES III Phase I sample represents the total noninstitutionalized civilian population, ages 2 months or older, in all 50 states of the US during 1988 -1991. Certain groups of interest (e.g., the elderly, blacks, Mexican-Americans) were oversampled to allow adequate representation of such subgroups.
Apo AI and apo B were measured in persons ages 4 years or older. Serum samples were obtained by venipuncture from both fasting and nonfasting persons examined in mobile examination centers and in the home. Examinees were instructed to fast as follows. For individuals examined in the morning, those ages 12-19 years were instructed to fast 8.5 h before examination; adults were instructed to fast 12 h before examination. Subjects examined in the afternoon or evening were instructed to fast Ն6 h. Children ages Ͻ12 years were instructed not to fast. For this analysis, fasting subjects were defined as those who reported fasting for 9 h or more. Nonfasting subjects were those who reported fasting Ͻ9 h.
The NHANES III (1988 -1991) population sample consisted of 16 919 persons ages 4 years or older. Of these, 14 269 were interviewed (84.3%) and 12 907 were interviewed and examined in mobile examination centers or at home, for an overall response rate of 76.3%. Apo B measurements were made in 11 483 subjects (67.9%), and apo AI in 11 432 subjects (67.6%). Selected characteristics known to affect serum lipoprotein concentrations (i.e., fat intake, alcohol consumption, use of exogenous hormones, smoking status, body mass index, physical activity) did not differ from those in subjects for whom apolipoprotein measurements were not made any more than would be expected by chance alone (data not shown). Approximately 6% of the adults in the study population as a whole and 5% of the female hormone users were taking ␤ blockers. Response rates were 72-73% in persons ages 20 years or older, 81-83% in those ages 12-19 years, and 85-86% in those ages 4 -11 years. There were no differences in response rates for males and females in any age group.
Women were classified as hormone users if at the time blood samples were drawn they said they were taking birth control pills, taking estrogen or hormone pills, using vaginal cream or suppositories, receiving hormone injections, or using hormone patches [40] . Otherwise they were classified as nonhormone users. Alcohol consumption was estimated from the self-reported number of times per day that beer, wine, and liquor were consumed over the 1-month period before examination [40] . Physical activity was determined from the total number of times per day that the individual reported walking, running, or jogging, riding a mobile or stationary bicycle, swimming, doing aerobic exercise or aerobic dancing, doing other dancing, calisthenics, weight-lifting, gardening, or other forms of exercise during the 1-month period before examination [40] .
laboratory methods
Blood sampling and shipment. Blood was drawn from subjects in the sitting position and allowed to clot for 45 min at room temperature. An aliquot of the serum was transferred to a screw-capped polypropylene storage vial and stored at Ϫ20°C for up to 1 week before being packed on solid CO 2 and sent to the laboratory by an overnight express delivery service. The samples were stored in the laboratory at Ϫ20°C for 1-2 weeks before analysis.
Apolipoprotein analysis. Samples were thawed at room temperature and mixed thoroughly for 30 min on a bloodrotating device before analysis. The procedures used for apo AI and apo B analysis have been described in detail [41] . Briefly, apo AI and apo B were measured by radial immunodiffusion (RID) in the first 8.2% (1055 specimens) of the specimens during the first 5 months of the study, and by rate immunonephelometry (INA) for the remaining specimens during the last 31 months. During the latter period, a 20% random subset of the samples were also analyzed by RID to establish the relationships between RID and INA [41] . After confirming that the RID method had remained stable between the initial 5-month period and the subsequent 31-month period, the RID values for the first 5 months were converted to equivalent INA values as described previously [41] . The apolipoprotein method was changed primarily because it became evident shortly after the study began that automated methods were becoming more widely used and we were unsure whether the RID kits then being used [41] would continue to be available for the entire study. We therefore decided to make this change at the beginning and in such a way that would allow the RID and INA data to be pooled and that could be adequately documented [41] .
At the beginning of the survey there were no standardized reference materials on which to base the measurements. Over the past few years, the WHO-IFCC First International Reference Materials for Apolipoproteins AI and B became available. The Northwest Lipid Research Laboratories, Seattle, WA, served as the coordinating laboratory for the development of these materials. For this reason, aliquots of the same random 20% subset of samples mentioned above were sent to that laboratory for analysis, and the results were used to transform the INA values to equivalent WHO-IFCC International Reference Materials-based values [41] , which are presented here. The procedures used for QC have been described previously [41] . The CVs for apo AI and apo B averaged Ͻ6% throughout the study.
lipid and lipoprotein measurements
Serum cholesterol and triglycerides and HDL and LDL cholesterol were measured as described previously [42] . The lipids were measured enzymatically with the use of commercially available reagents (Cholesterol/HP, cat. no. 816302, and Triglycerides/GPO, cat. no. 816370, both from Boehringer Mannheim). HDL cholesterol was measured in the clear supernatant after precipitating the other lipoproteins with heparin and MnCl 2 (1.3 g/L and 0.046 mol/L, respectively) and removing excess Mn 2ϩ by precipitation with NaHCO 3 , as described previously [43] . The biases (CVs) averaged Ϫ0.3% (1.7%), Ϫ2.1% (3.9%), and 0.3% (3.4%) for cholesterol, triglycerides, and HDL, respectively.
LDL was calculated from the three primary measurements with the use of the Friedewald equation [44] :
where concentrations are given in g/L and the factor [TG]/5 is an estimate of VLDL cholesterol concentration. LDL cholesterol values were calculated only for fasting subjects with triglyceride concentrations of 4.00 g/L or below. Non-HDL cholesterol was calculated as the difference between total cholesterol and HDL cholesterol and represents the total concentration of cholesterol in all of the lipoproteins except HDL.
statistical analyses
The apo AI and apo B results presented here were estimated with the use of sampling weights. Each individual in whom apo AI and apo B measurements were made was assigned a sample weight that corresponds to the number of people in the US population represented by that individual. The sample weights incorporate the differential probabilities of selection, adjust for oversampling of subgroups of interest, and include adjustments for nonresponse. The estimates of apo AI and apo B presented here are based on weighted data [40] and are representative of the noninstitutionalized civilian population of the US. The reliability and precision of means and percentiles were determined according to standard statistical methods, as described previously [40] . The minimum sample sizes used for different percentiles were those recommended by NCHS [40] . [45, 46] . The hypothesis that mean apo AI and apo B concentrations of hormone replacement users and nonusers were equal was tested at the 0.05 significance level by a Student's t-test statistic.
For the purpose of assessing the sensitivity and specificity of apo B measurements as indicators of LDL cholesterol concentrations in the increased-risk ranges of concentration, sensitivity was defined as the proportions of subjects with LDL cholesterol concentrations Ն1.30or Ն1.60 g/L who were correctly identified by virtue of having apo B concentrations above cutoffs that were selected to maximize sensitivity and specificity. These apo B concentrations were 1.07 g/L to detect LDL cholesterol Ն1.30 g/L and 1.27 g/L to detect LDL cholesterol Ն1.60 g/L. Specificity was defined as the proportions of subjects with LDL cholesterol concentrations Ͻ1.30 or Ͻ1.60 g/L who were correctly classified by virtue of having apo B concentrations below the respective apo B cutpoints. For apo AI, sensitivity was defined as the proportions of subjects with HDL Ͻ0.35 g/L or with HDL Ն0.60 g/L who were correctly identified by virtue of having apo AI concentrations Ͻ1.14 or Ͼ1.54 g/L, respectively. These were the apo AI concentrations that maximized sensitivity and specificity at the respective HDL cholesterol cutpoints. Apo AI specificity was defined as the proportion of subjects with HDL cholesterol Ն0.35 g/L or Ͻ0.60 g/L who had apo AI concentrations Ͼ1.14 g/L or Ͻ1.54 g/L, respectively.
Results
For this communication, the results are presented for non-Hispanic whites (referred to as whites), non-Hispanic blacks (referred to as blacks), and Mexican-Americans, the three major race/ethnic groups in this study. The characteristics of the study population are shown in Table 1 . By design, 50% of the study subjects were males; 54% had fasted at least 9 h before blood sampling.
apo b in fasting and nonfasting subjects
The National Cholesterol Education Program Adult Treatment Panel II guidelines [47] recommend that LDL cholesterol measurement be made only in patients that have fasted for Ն9 h. We therefore compared apo B values in subjects who reported fasting 9 h or more with those in subjects who reported fasting Ͻ9 h. These comparisons were made for all three race/ethnic groups stratified by age and sex. There were no significant differences in apo B concentrations in fasting and nonfasting subjects. We also examined apo B concentrations in persons fasting Ͻ6 h compared with those fasting Ն9 h, stratified by sex, in all subjects and in the non-Hispanic whites (data not shown). Again, significant differences were not observed any more than would be expected by chance. Therefore, for the following comparisons the data from fasting and nonfasting subjects were pooled.
apo b by ethnic group
There was no significant difference in the age-adjusted mean Ϯ SE apo B concentrations in all males (0.99 Ϯ 0.01 g/L) compared with all females (0.97 Ϯ 0.01 g/L).
The age-adjusted mean apo B concentration for the three ethnic groups are shown in Table 2 for children (ages 4 -11 years), adolescents (ages 12-19 years), and adults (ages Ն20 years). Overall, the age-adjusted apo B concentrations in males and females were similar; this was true in all three ethnic groups. Black adult men had a slightly, but significantly lower, age-adjusted mean apo B concentration than whites or Mexican-Americans, whereas the means in females were about the same for all ethnic groups. The concentrations remained stable throughout childhood and adolescence, then increased in adulthood. This increase was 37-38% in white and Mexican-American males and ϳ28% in black males. For females, the increase was ϳ26% for all three ethnic groups ( Table 2 ). The cumulative distributions of apo B in the three ethnic groups are shown in Fig. 1 . These distributions for black males and females revealed lower apo B concentrations than in whites or Mexican-Americans, but the difference was greatest for the males (Fig. 1 ).
apo b by age
Selected percentiles for apo B are shown in Table 3 . Median apo B concentrations in males were 0.75-0.79 g/L in the age groups from 4 to 19 years. There was an abrupt increase in apo B concentrations in adult men that continued from ages 20 -50 years, reached a plateau in those ages 50 -69 years, and tended to decrease after age 69 years ( Fig. 2 ). In females, the median apo B concentrations in the groups ages 4 -19 years were 0.79 -0.82 g/L. Again, the concentrations increased abruptly after age 20 years and reached a plateau after age 60 years ( Fig. 2 ). Because this was a cross-sectional study, it cannot be determined whether the lower apo B values observed in the oldest groups were due to a decline in apo B values or to selective mortality in those with higher apo B values, although the latter factor almost certainly operated. In both males and females, the concentrations of LDL cholesterol also increased with age, and the increases were similar to those observed with apo B (Fig. 2) .
The apo B pattern in women differed from that in men, however, in the appearance of a double plateau, one that occurred in groups ages 20 -49 years and a second that occurred after age 59 (Fig. 2) . The occurrence of the first plateau in the younger women suggested the presence of hormonal influences, possibly related to premenopausal hormone use, postmenopausal changes, or both. For this reason, we examined apo B concentration in adult women after stratification for hormone use. In the group ages 20 -49 years, hormone users had significantly higher apo B concentrations than nonusers ( Fig. 3 ). After age 50, however, their apo B concentrations tended to be slightly lower than in nonusers, but the differences were not statistically significant ( Fig. 3 ). Furthermore, the double plateau pattern apparent in the entire population was not seen in the nonusers and had apparently resulted from hormone use in some of the younger women.
We also examined LDL cholesterol concentrations in hormone users and nonusers among adult women (Fig. 3 ). The number of fasting hormone users was insufficient to allow age stratification by decade, and wider age strata were used. The LDL cholesterol concentrations in users and nonusers were similar in the groups ages 20 -39 years and 40 -59 years, but tended to be lower in hormone users after age 60 (P ϭ 0.062). Overall, LDL cholesterol increased ϳ19% between ages 20 and 60 in hormone users and ϳ35% in nonusers. This compared with an ϳ27% increase in apo B in users and a 42% increase in nonusers over the same period. Age-adjusted mean apo B concentrations were significantly higher in users than nonusers for the groups ages 20 -49 years and significantly lower after age 50 (Table 4 ). LDL cholesterol tended to be slightly lower in hormone users overall (Table 4 ), primarily because of the lower LDL cholesterol in users over age 60 (Fig. 4) . As a consequence, the age-adjusted ratio of LDL cholesterol to apo B concentrations was significantly lower in users than in nonusers (P Ͻ0.001) ( Table 4 ). Triglycerides tended to be slightly higher in hormone users. Both male and female apo B concentrations ultimately reached about the same concentration (ϳ1.20 g/L), but in males this occurred ϳ10 years earlier than in females. For the various age and sex strata, the differences between the mean and median values ranged from 0 to 0.05 g/L. This proximity of the means and medians to each other and the reasonably low skewness values for the various individual age and sex strata (range 0.02 to 1.40) and the skewness value for the entire population (0.74) suggested that the distribution of apo B was only slightly skewed. 5 There was a reasonably high correlation between serum apo B and LDL cholesterol (r ϭ 0.87) (see also Fig. 2 ), and the correlation was the same in males and females. In all cases the mean and median LDL cholesterol/apo B ratios were similar (data not shown). As expected, there was slightly higher correlation (r ϭ 0.92) between serum apo B and non-HDL cholesterol. Non-HDL cholesterol is a measure of the amount of cholesterol associated with LDL plus the other apo B-containing lipoproteins, i.e., VLDL, IDL, and Lp(a). Because the LDL cholesterol in the NHANES III survey was estimated with the use of the Friedewald equation [44] , however, the measurements included the contributions of both IDL and Lp(a) (discussed in ref. 48) . The slightly greater correlation between apo B and non-HDL cholesterol was, therefore, due to the contribution of VLDL to non-HDL cholesterol.
Ranges of apo B concentration were determined for adults ages 20 years and older with LDL cholesterol concentrations in the various risk-related ranges established by current National Cholesterol Education Program guidelines for persons without CHD [47] . Table 5 shows the mean apo B concentration and the 5th through 95th percentile ranges for subjects with desirable (Ͻ1.30 g/L), borderline high (1.30 -1.59 g/L), high (1.60 -1.89 g/L), and very high (Ն1.90 g/L) LDL cholesterol concentrations. There was a considerable overlap in apo B concentration from one LDL cholesterol risk group to the next. For example, the 5th-95th percentile range of apo B concentrations observed in those with LDL cholesterol concentrations Ͻ1.30 g/L was 0.61-1.16 g/L, whereas that in subjects with LDL cholesterol concentrations of 1.30 -1.59 g/L was 0.94 -1.38 g/L. Similarly, there was a 0.26 g/L overlap between the groups with borderline and high LDL cholesterol concentrations. Thus, it was not possible to use apo B concentrations alone to classify subjects reliably into LDL risk categories. On the basis of the findings in Table 5 , apo B measurements would be expected to distinguish those with desirable LDL cholesterol concentrations from those with high or very high concentrations, but those with borderline LDL cholesterol concentrations could not be distinguished from the other two groups reliably. This is perhaps not too surprising given the variation in LDL composition that occurs among individuals and the fact that apo B is found in all of the lipoproteins except HDL. The extent to which apo B reflects LDL cholesterol depends in part on the concentrations of the other apo B-containing lipoproteins. For example, we found that only 1.8% of the subjects with LDL cholesterol Ͻ1.30 g/L and triglycerides Ͻ2.00 g/L had apo B concentrations Ͼ1.16 g/L, the 95th percentile for subjects with desirable LDL cholesterol concentrations. In contrast, 27.4% of the subjects with LDL cholesterol in the desirable range and triglycerides of 2.00 -4.00 g/L had apo B concentrations Ͼ1.16 g/L. The relative contributions of apo B-containing lipoproteins other than LDL (as opposed to LDL subfractions containing a lower than average ratio of cholesterol to apo B) to the higher apo B concentrations in the latter subgroup cannot be assessed from the present data. Table 5 also shows the 25th through 75th percentiles for apo B concentration in the various LDL cholesterol risk categories. With the use of these percentiles, there was very little overlap in apo B concentrations between risk categories, but these percentiles exclude a substantial proportion of the population. Furthermore, 19.8% of the subjects with desirable-range LDL cholesterol and triglycerides Ͻ2.00 mg/L had apo B concentrations Ͼ0.99 g/L, the 75th percentile for individuals with LDL cholesterol Ͻ1.30 g/L. For those with desirable LDL cholesterol and triglycerides of 2.00 -4.00 g/L, 62.8% had apo B concentrations Ͼ0.99 g/L.
We also examined the overall sensitivity and specificity of apo B for identifying individuals with LDL cholesterol concentrations Ͼ1.30 and Ͼ1.60 g/L, irrespective of triglyceride concentration. For this purpose, we used apo B cutpoints that maximized both sensitivity and specificity: 1.07 g/L for LDL Ն1.30 and 1.27 g/L for LDL Ն1.60 g/L. Apo B had a sensitivity of 82.6% and a specificity of 85.6% for classifying subjects with LDL Ն1.30 g/L, indicating that 14.4% of subjects with desirable LDL cholesterol (i.e., ϳ8% of the entire study population) would have been misclassified as having an LDL cholesterol of 1.30 g/L or higher, whereas ϳ20% of subjects whose LDL cholesterol actually exceeded this concentration (7.7% of the total study population) would also been misclassified. Thus, 15.7% of the of the total study population would have been misclassified. The sensitivity and specificity of apo B in identifying subjects with LDL cholesterol of 1.60 g/L or higher were 71.2% and 93.6%, respectively. In this case, 28.8% of subjects with a high LDL cholesterol (5.3% of the total population) and 6.4% of those with LDL Ͻ1.60 g/L (5.2% of the total population) would have been misclas-sified, for an overall misclassification rate of 10.5% with respect to the entire population.
apo ai in fasting and nonfasting subjects
The effect of fasting status on the estimates of apo AI concentration was examined as discussed above for apo B. Again, no significant differences were observed between fasting and nonfasting subjects (data not shown). Therefore, the data from both were pooled for the following analyses.
apo ai by ethnic group
The mean Ϯ SE apo AI concentration in males (1.36 Ϯ 0.01 g/L) was 0.10 g/L lower than in females (1.46 Ϯ 0.01 g/L). As seen from the age-adjusted apo AI values in Table 2 , the male-female differences for all whites, ages 4 years or older (0.12 g/L), was twice that for all blacks (0.06 g/L). The difference in Mexican-Americans (0.09 g/L) was intermediate between whites and blacks. The age-adjusted apo AI concentration in all black males (1.45 g/L) was 0.11 g/L higher than in white males (1.34 g/L), whereas that in Mexican-American males (1.35 g/L) was essentially the same as in white males ( Table 2 ). The apo AI concentration in black females was significantly higher (1.51 g/L) than in white females (1.46 g/L) or Mexican-American females (1.44 g/L) ( Table  2 ). The cumulative distributions of apo AI for black males and females revealed higher apo AI concentrations than in the other two ethnic groups, but as observed for apo B, the difference was greatest in the males (Fig. 4 ).
apo ai by age
Selected percentiles for apo AI are shown in Table 6 . Median apo AI concentrations in males remained essen- tially constant with age and ranged from 1.28 to 1.36 g/L in all age ranges except the group ages 6 -11 years, which had a median value of 1.41 g/L (Fig. 5 ). The overall pattern of apo AI concentrations in females differed from that in males because the median apo AI values tended to increase with age, then reached a plateau in the groups ages Ն50 years (Fig. 5 ). There appeared to be somewhat less concordance between apo AI and HDL cholesterol than between apo B and LDL cholesterol in both males and females (Fig. 5) . Thus, whereas apo AI tended to remain rather constant with age in males and to increase with age in females, there appeared to be a slight downward trend in HDL in both sexes (0.02 to 0.03 g/L) in the groups with ages between 20 and 69 years (Fig. 5 ). Thecorrelation between apo AI and HDL cholesterol was 0.74 in males and 0.78 in females. There appeared to be a fairly pronounced double plateau in women. The first occurred in the groups ages 20 -39 years, and the second after age 50 (Fig. 5 ). This double plateau thus occurred over the same age ranges as for apo B in women, again suggesting the possible influence of hormone use or hormonal changes that affect apo AI concentrations in women. Unlike the pattern observed with apo B, however, stratification of the adult women according to hormone use revealed that the double plateau persisted in the nonhormone users, the first occurring in the groups ages 20 -49 years and the second after age 50 years (Fig. 6 ). Hormone users had uniformly higher apo AI concentrations than nonusers at all ages, and significantly higher HDL cholesterol concentrations in the groups ages 40 -69 years. In addition, the age-adjusted concentrations of both apo AI and HDL cholesterol were significantly higher in hormone users. The age-adjusted ratios of apo AI to HDL cholesterol in hormone users and nonusers were virtually identical (Table 4 ), however, indicating that apo AI and HDL cholesterol were affected similarly by hormones.
In all the age subgroups of males and females, the mean apo AI concentration ranged from 0.01 to 0.05 g/L higher than the median ( Table 6 ). The skewness values for the various sex and age strata ranged from 0.24 to 1.28 and that for the entire population was 0.95. As for apo B, the proximity of the means and medians to each other and the reasonably low skewness values 5 for the various strata suggested that the distributions were slightly skewed.
To determine the sensitivity and specificity of apo AI for classifying individuals with low (Ͻ0.35 g/L) or high (Ն0.60 g/L) HDL cholesterol, we used apo AI cutpoints that maximized sensitivity and specificity: 1.14 g/L for low HDL cholesterol and 1.54 g/L for high HDL cholesterol. For low HDL, the sensitivity was 52.1%, and the specificity was 95.1%. Thus, apo AI misclassified 47.9% of the subjects with low HDL (5% of the total population), and 4.9% of those with HDL cholesterol Ն0.35 g/L (4% of the population), for an overall misclassification rate of ϳ9% with respect to the total population. Apo AI was somewhat better at classifying subjects with high HDL cholesterol, for which the sensitivity and specificity were 70.0% and 89.0%, respectively. Thus 30% of individuals with HDL cholesterol Ն0.60 g/L (8% of the population) and 11% of those with HDL cholesterol Ͻ0.60 g/L (8% of the population) would be misclassified, resulting in a misclassification rate of 16% in the total population.
correlates of apo ai and apo b concentrations
To control for the confounding effects of various possible correlates on apo AI and apo B concentrations, we per- formed multiple linear regression analyses with either apo AI or apo B as the dependent variable ( Table 7) . The independent variables in the regression models included hormone use, age, sex, race, body mass index, alcohol consumption, cigarette smoking, physical activity, and years of education. The strong and direct association between hormone use and apo AI concentrations in females persisted after controlling the other variables (P Ͻ0.001). The analysis indicated that in female hormone users, the apo AI concentrations were 0.168 g/L higher than in others. As expected, age, female sex, black race, alcohol consumption, and years of education were independently and directly associated with apo AI. Body mass index and current cigarette smoking were independently and inversely associated with apo AI concentration. Female sex, alcohol use, and hormone use were associated with larger effects on apo AI, whereas body mass index, age, black race, current smoking, and higher education were associated with smaller effects ( Table 7) .
For the most part, the opposite relationships were observed between these correlates and apo B concentrations (Table 7) . Female sex, hormone use, and black race were independently and inversely related to apo B concentrations, whereas body mass index and current cigarette smoking were independently and directly related to apo B concentrations. Past cigarette smoking was also independently related to apo B concentration (P Ͻ0.05), but not to apo AI concentration; years of education were independently related to apo AI (P Ͻ0.05) but not to apo B concentration.
Discussion
Serum apo AI and B concentrations were measured in ϳ12 000 individuals ages 4 years and older in a national probability sample of the noninstitutionalized population of the US as part of NHANES III, Phase I. The pattern of apo B variation with age in women was different from in men. Whereas apo B concentration in men tended to increase continually in adulthood, those in women tended to reach a plateau between ages 20 and 40 years, and the rate of increase in premenopausal women was slower than in men of the same age. This was related primarily to hormone use in the younger women, because the increase with age in women who did not use hormones was similar to that in men but occurring ϳ10 years later. In contrast, the agerelated increase in apo B in hormone-using younger women more closely resembled that in men. The age-related changes in LDL cholesterol in both men and women were similar to the changes in apo B. Apo B concentrations tended to be higher in adult female hormone users than in nonusers, ages 20 -49 years, but LDL cholesterol concentrations in hormone users and nonusers were similar during this period. Lower LDL cholesterol was observed only in hormone users after age 60. These findings are similar to those reported in the Lipid Research Clinics program, in which LDL cholesterol was lower in hormone users only after age 50 [49] .
The mean apo AI concentration in all males was ϳ7% lower than in females, reflecting male-female differences in HDL cholesterol concentrations [42, 50] . The male-female difference in whites, however, was ϳ1.5-fold greater than in the other two ethnic groups. Overall, apo AI concentrations in men tended to remain constant with age.
In females, the age-related pattern was markedly different. Apo AI concentrations were lowest in childhood and adolescence and tended to increase continually through adulthood. As observed for apo B, apo AI in females also tended to plateau in the groups ages 20 -40 years, then increased to a maximum concentration of 1.54 g/L thereafter. Unlike apo B, however, this remained true in both the hormone-and non-hormone-using women, indicating that the more gradual increase in apo AI with age in premenopausal women was not related to the use of exogenous hormones. Apo AI concentrations were higher in adult women using hormones than in nonusers at all ages, but HDL cholesterol concentrations were significantly higher in hormone users only after age 40. Again, the pattern of higher HDL cholesterol in older female hormone users has been observed by others [49] .
The differences observed between either apo AI or apo B concentrations in subjects that had fasted at least 9 h compared with those who had fasted for shorter periods were no greater than expected by chance alone. About 16% of the subjects had fasted Ͻ6 h and 30% reported their last food intake to be 6 -8 h before venipuncture. Although one cannot conclude with certainty that some postprandial changes may not have occurred in the 2-4-h postprandial period, when the increase in plasma triglycerides and the appearance of partially metabolized intestinal lipoproteins would be maximal, it is reasonable to infer that if such changes occurred they would have been minor, and the results suggested that both apolipoproteins can be measured in either fasting or nonfasting individuals.
In view of the variety of methods used for apolipoprotein analysis, the previous lack of common reference materials to which the calibration of the methods could be referred, and the different populations in which these measurements have been made [9, 20, 22, 27, 31, [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] , it is difficult to compare the apo AI and B values reported in different studies [48, 53] . However, the age-related changes in apolipoprotein concentrations as reported in several earlier studies can be compared. Kottke et al. [57] reported that apo B concentrations increased with age in males and females in the Rochester Family Heart Study. Similar observations were reported by Schaefer et al. [31] in the Framingham Offspring Study, Vermaak et al. [54] in South Africa, Kinlay et al. [55] in Australia, Zunic et al. [60] in healthy blood bank volunteers in Yugoslavia, and Brown et al. [62] in the Atherosclerosis Risk in Communities Study. The age-related increases were most prominent in women [31, 55] . On the other hand, Sarihyan et al. [56] found little change in apo AI with age in either males or females. Brown et al. [62] also found no change in apo AI with age in the Atherosclerosis Risk in Communities Study, although the changes we observed in the present study occurred primarily at younger ages than those they studied [62] . There also appeared to be only a slight tendency for apo AI and apo B to increase with age in a subset of the Lipid Research Clinics population in Seattle [51, 52] , whereas Noma et al. [53] reported an age-associated decrease in apo AI, but apo B increased with age in both males and females. The reasons for the apparently conflicting findings are not immediately apparent, although changes in apolipoprotein concentrations with age may well be different in different populations. The results of such studies must be interpreted cautiously, however, because most were conducted in much smaller populations or over a more restricted age range than we exam-ined. In the present study, there was a clear increase in apo B concentration with age in both males and females, and the increase in non-hormone-using women occurred at least 10 years later than in men. Furthermore, the patterns of age-related changes in apo AI concentrations differed in males and females; apo AI concentrations tended to increase only in females and, as observed by others [62] , were higher in hormone-treated women.
In most cases serum apo B reflects primarily the apo B in LDL. In addition apo B appears to be at least as good a discriminator of CHD as LDL cholesterol. The question therefore arose whether apo B measurements might be used reliably as a surrogate for LDL cholesterol measurements to classify subjects according to National Cholesterol Education Program risk amounts for LDL cholesterol. However, with an apo B cutpoint of 1.54 g/L, which was selected to maximize the sensitivity and specificity of the test, the sensitivity of apo B for identifying individuals with high LDL cholesterol, i.e., Ͼ1.60 g/L, was only ϳ70%; thus the measurement would be expected to misclassify ϳ30% of those with high LDL cholesterol, a misclassification rate that in our opinion is unacceptably high. However, apo B might be used to classify at least some individuals. On the basis of the findings in Table 5 , apo B values Ͻ0.61 g/L or Ͼ1.57 g/L would reliably identify individuals with LDL cholesterol Ͻ1.30 g/L and Ն1.60 g/L, respectively. Within the range 0.61-1.57 g/L, it would be difficult to distinguish between desirable, borderline high, and high risk classifications. Furthermore, the misclassification of individuals with desirable LDL cholesterol concentrations would be considerably greater in those with triglyceride concentrations of 2.00 -4.00 g/L, compared with those with lower triglyceride concentrations.
For several reasons, these findings are perhaps not too surprising. First, each of the apo B-containing particles [VLDL, IDL, LDL, and Lp(a)] contains one molecule of apo B per particle, and all except VLDL are potentially atherogenic. Apo B, therefore, can be considered a measure of the number of potentially atherogenic particles present. Second, LDL cholesterol is usually calculated from measurements of total cholesterol, triglycerides, and HDL cholesterol [44] and was estimated in this way in NHANES III [42, 50] . However, these LDL cholesterol measurements also contain the contributions of cholesterol from IDL and Lp(a). On average, these lipoproteins contribute ϳ0.02-0.04 g/L to the LDL cholesterol measurement, but can contribute more in individual patients. Furthermore, the cholesterol content of each of the lipoproteins can vary somewhat among individuals. Thus, LDL cholesterol reflects several characteristics of several lipoproteins: the relative concentrations of LDL, IDL, and Lp(a) within an individual; the different cholesterol compositions of these three lipoproteins within an individual; and the various cholesterol compositions of each of these lipoproteins among individuals.
The question of whether apo B might eventually be used instead of LDL cholesterol as the basis for assessing risk for CAD remains open. Several recent studies suggest that an increased apo B increases the risk for future coronary events [32] [33] [34] [35] [36] [37] , but much further work is required to determine whether apo B satisfies accepted epidemiological criteria for establishing causality between high apo B concentration and CAD. Furthermore, the question remains whether the total number of apo Bcontaining particles present (as reflected by the apo B concentration), the concentration of cholesterol in these particles (as reflected by the LDL cholesterol measurement), or both considered together would be the more sensitive indicator(s) of risk for CAD.
Similar considerations apply for apo AI. It seems clear, however, that the lower correlations observed between apo AI and HDL cholesterol than between apo B and LDL cholesterol and the low sensitivity of apo AI for identifying patients with low HDL cholesterol concentrations would make it even more difficult to use apo AI as a surrogate measure of HDL cholesterol. Again, further research is required to determine whether the measurement of apo AI itself may provide a more sensitive indication of risk for CHD than HDL cholesterol currently provides.
Two final points should be considered that deal with the nature of the samples used for the NHANES III survey. First, by design, specimens collected in NHANES surveys were frozen and stored briefly before and after shipment to the laboratory (see Methods). While the possible effects of freezing on the apolipoprotein measurements were not evaluated in the present study, in several published studies freezing for periods of 1 month to 3 years at Ϫ20°C or lower did not significantly change apo AI values [38, 51, 64, 65] . For apo B, several investigators reported that frozen storage at Ϫ20°C for periods ranging from 1 week to 6 months [66 -68] or for 1 month at Ϫ80°C [39] had no substantial effect on apo B values. On the other hand, Kafonek et al. [69] found a slight (6.5%) decrease in apo B values in Ͼ200 samples stored at Ϫ70°C for almost 2 years. Brown et al. [70] , reporting a similar decrease in 20 specimens stored at Ϫ70°C for 6 weeks, attributed the decrease to the acute effect of freezing rather than to storage-related losses. In a recent examination of the acute effects of freezing on apo B measurement in Ͼ100 samples, however, we observed no detectable change when the samples were analyzed 24 h after freezing (unpublished observations). Considered together, the various studies suggest that the use of freshfrozen samples probably did not affect apo AI values, and if freezing, per se, affects apo B at all, the effect in the present study was probably minor.
Additional, albeit indirect, support for these conclusions is also evident when comparing the present apo AI measurements with those measured by Contois et al. [38] in the Framingham Offspring Study. In both studies the apolipoprotein measurements are based on WHO-IFCC standards, which allows such a comparison. The mean apo AI values by age decade for males and females in the age decades common to both studies (i.e., adults ages 30 years or older) were almost identical, despite apo AI measurements in the Framingham Offspring Study being made in samples that had been stored for 4 -6 years at Ϫ80°C [39] . A similar comparison for apo B, however, again with the use of the findings of Contois et al. [39] shows that the mean apo B values by decade averaged ϳ10% lower in the Framingham Offspring Study than in NHANES III. The basis for this difference is not certain. It may reflect actual differences in the two study populations, but might also have resulted in part from a fairly slow deterioration of apo B during the 4 -6-year period that the Framingham Offspring Study samples were stored before analysis [39] .
The second issue is the possible effect of sample turbidity, which generally occurs in samples with triglycerides Ͼ4.00 g/L and can influence immunonephelometric and immunoturbidimetric methods. For several reasons, it is unlikely that sample turbidity affected the results reported here. First, the NHANES III, Phase 1 subjects were selected to represent a normal population. The average triglyceride, by decade, ranged from 1.00 to 2.00 g/L [42] , and there were only 60 individuals (0.5% of the Phase I population) with triglycerides exceeding 4.00 g/L. Second, detergent-containing buffers were used in the analytical methods to minimize turbidity and optimize immunoreactivity. Third, the instrumentation we used flagged samples that were too turbid to be analyzed directly and that had to be diluted for analysis. Finally, as we noted above, apo AI and apo B concentrations were the same in fasting and nonfasting subjects, suggesting that sample turbidity would not have markedly influenced the measurements in the NHANES III survey.
To our knowledge, this is the first national survey of apo AI or apo B distributions in the entire US population and the second US study in which the measurements can be referred to the new WHO-IFCC International Reference Materials for apo AI and apo B. The availability of these materials should now make it possible to compare apo AI and apo B concentrations in different studies and populations and ultimately lead to the development of common, risk-based cutoffs for these apolipoproteins similar to those currently used for LDL and HDL [47] .
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